Viewing Study NCT02634320



Ignite Creation Date: 2024-05-06 @ 7:57 AM
Last Modification Date: 2024-10-26 @ 11:54 AM
Study NCT ID: NCT02634320
Status: COMPLETED
Last Update Posted: 2018-12-04
First Post: 2015-12-16

Brief Title: A Study of Aripiprazole Lauroxil Also Known as ARISTADA TM in Subjects With Schizophrenia
Sponsor: Alkermes Inc
Organization: Alkermes Inc

Study Overview

Official Title: Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection
Status: COMPLETED
Status Verified Date: 2018-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will evaluate the safety and tolerability of aripiprazole lauroxil also known as ARISTADA ALKS 9070
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None